|
|
Gastrointestinal agent
|
|
Proton pump inhibitor
|
|
Dual therapy,pathologic hypersecretory conditions,gastric ulcer,severe erosive Esophagitis, Stomach ulcer, inflammation of the esophagus, Heart Burn, Reflux disease, treatment of stomach infection by H. pylori in combination with other drugs.
|
|
20-40 mg once daily.
|
|
Category C
|
|
Headache, Diarrhea, abdominal pain, nausea, dizziness, vomiting, Constipation, allergic reactions, abdominal pain, serum Gastrin levels rise in most patients during first 2 weeks of therapy, back pain, upper respiratory infection, rash.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|